Trial · NCT01855724
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
NCT01855724, Phase 2, Terminated, Hellenic Cooperative Oncology Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer. Trials, record NCT01855724. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01855724
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
- NCT number
- NCT01855724
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Biliary Carcinoma
- Interventions
- Gemcitabine-Pazopanib
- First posted
- 2013-05-16
- Last updated
- 2018-11-07
- Other registries' IDs
- eudract:2012-001705-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) | At an average of 6 months for each patient | Imaging evaluation for the determination of response to treatment will be performed every 8 weeks |
| Secondary | Evaluation of Progression-Free Survival (PFS) | PFS will be calculated from the date of treatment initiation to the date of disease progression or date of death, assessed up to 48 months | |
| Secondary | Evaluation of 6-month Progression-Free Survival rate (6-month PFS rate) | Assessed up to 6 months | The aim is to determine the rate of PFS in patients, at 6 months of treatment |
| Secondary | Evaluation of Overall Survival (OS) | OS will be calculated from the date of treatment initiation to the date of death from any cause, assessed up to 48 months. | |
| Secondary | Assessment of safety and tolerability | Assessed up to 48 months | Distribution of Adverse Events (AEs) according to severity grade. Evaluation of AEs will be performed every 21 days (per treatment cycle) throughout the course of treatment |
| Secondary | Evaluation of Quality of Life (QoL) | Assessed up to 9 months | Quality of Life Questionnaires will be filled out before treatment initiation, every 8 weeks and at the end of treatment |
| Secondary | Evaluation of potential prognostic and/or predictive biomarkers in tissue and blood samples | Tumor blocks and blood samples will be collected at baseline | The following biomarkers will be analyzed: In bioptic material: * Stem Cell Factor (KIT) * Vascular Endothelial Growth Factor Receptor-2 (VEGF-2) * Vascular Endothelial Growth Factor Receptor-3 (VEGF-3) In peripheral blood/plasma: * Interleukin 8 * Interleukin 12 * Hepatocyte growth factor There may be additions to the biomarkers to be analyzed, dependent on the clinical and bibliographical data |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01855724
GET https://conductscience.org/api/trials/v1/NCT01855724/registered